Can a common blood thinner outsmart a hidden heart risk?
NCT ID NCT07720934
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
About 1 in 5 people have genetically high levels of lipoprotein(a), a sticky fat that raises the risk of blood clots and heart disease. This pilot study asks whether one standard antiplatelet drug—aspirin or clopidogrel—is better at calming overactive platelets in these individuals. Sixty adults with high Lp(a) will take each drug for two weeks in a crossover design, and researchers will measure changes in platelet activity and related blood markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aspirin and clopidogrel, two standard antiplatelet drugs
- What this could lead to
- If one drug proves better at reducing platelet hyperreactivity, it could point toward a more tailored prevention strategy for the 20% of people with high Lp(a).
- What could go wrong
- This is a small pilot study with 60 participants, so results may not apply broadly. It compares existing drugs, not a new treatment, and may not change clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR PREVENTION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hopitaux Universitaires de Genève
Geneva, 1205, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.